Abstract
Neuronal Nitric Oxide synthase (nNOS) is an attractive challenging target for the treatment of various neurodegenerative disorders. To date, several structure-based studies were conducted to search novel selective nNOS inhibitors.
Objective: Discovery of novel nNOS lead scaffolds through the integration of ligand-based threedimensional (3D) pharmacophore (s) with quantitative structure-activity relationship model.
Method: The pharmacophoric space of ten structurally diverse sets acquired from 145 previously reported nNOS inhibitors was scrutinize to fabricate representative pharmacophores. Afterwards, genetic algorithm together with multiple linear regression analysis was applied to find out an optimal pharmacophoric models and 2D physicochemical descriptors able to produce optimal predictive QSAR equation (r2 116 =0.76, F = 353, r2 LOO = 0.69, r2 PRESS against 29 external test ligands =0.51). A minimum of three binding modes between ligands and nNOS binding pocket rationalized by the emergence of three pharmacophoric models in the QSAR equation were illustrated. The QSAR-selected pharmacophores were validated by receiver operating characteristic curves analysis and afterward invested as a tool for screening national cancer institute (NCI) database.
Results: Low micro molar novel nNOS inhibitors were revealed.
Conclusion: Two structurally diverse compounds 148 and 153 demonstrated new scaffolds toward the discovery of potent nNOS inhibitors.
Keywords: Neuronal nitric oxide synthase, quantitative structure activity relationship, In silico screening, pharmacophore modeling.
Medicinal Chemistry
Title:Pharmacophore and QSAR Modeling of Neuronal Nitric Oxide Synthase Ligands and Subsequent Validation and In Silico Search for New Scaffolds
Volume: 12 Issue: 4
Author(s): Ghadeer Suaifan, Mayadah Shehadeh, Hebah Al-Ijel, Khuloud T. Al-Jamal and Mutasem Taha
Affiliation:
Keywords: Neuronal nitric oxide synthase, quantitative structure activity relationship, In silico screening, pharmacophore modeling.
Abstract: Neuronal Nitric Oxide synthase (nNOS) is an attractive challenging target for the treatment of various neurodegenerative disorders. To date, several structure-based studies were conducted to search novel selective nNOS inhibitors.
Objective: Discovery of novel nNOS lead scaffolds through the integration of ligand-based threedimensional (3D) pharmacophore (s) with quantitative structure-activity relationship model.
Method: The pharmacophoric space of ten structurally diverse sets acquired from 145 previously reported nNOS inhibitors was scrutinize to fabricate representative pharmacophores. Afterwards, genetic algorithm together with multiple linear regression analysis was applied to find out an optimal pharmacophoric models and 2D physicochemical descriptors able to produce optimal predictive QSAR equation (r2 116 =0.76, F = 353, r2 LOO = 0.69, r2 PRESS against 29 external test ligands =0.51). A minimum of three binding modes between ligands and nNOS binding pocket rationalized by the emergence of three pharmacophoric models in the QSAR equation were illustrated. The QSAR-selected pharmacophores were validated by receiver operating characteristic curves analysis and afterward invested as a tool for screening national cancer institute (NCI) database.
Results: Low micro molar novel nNOS inhibitors were revealed.
Conclusion: Two structurally diverse compounds 148 and 153 demonstrated new scaffolds toward the discovery of potent nNOS inhibitors.
Export Options
About this article
Cite this article as:
Suaifan Ghadeer, Shehadeh Mayadah, Al-Ijel Hebah, Al-Jamal T. Khuloud and Taha Mutasem, Pharmacophore and QSAR Modeling of Neuronal Nitric Oxide Synthase Ligands and Subsequent Validation and In Silico Search for New Scaffolds, Medicinal Chemistry 2016; 12 (4) . https://dx.doi.org/10.2174/1573406411666151002130609
DOI https://dx.doi.org/10.2174/1573406411666151002130609 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Current Neuropharmacology Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity
Current Medicinal Chemistry Editorial - A Milestone for Current Alzheimer Research [Hot Topic: Neurogenesis Catalyst Conference (Guest Editors: Howard M. Fillit & Gunnar Gouras) ]
Current Alzheimer Research Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: The Medicinal Chemistry of Hybrid-Based Drugs Targeting Multiple Sites of Action (Guest Editors: Jose Marco-Contelles, & Elena Soriano)]
Current Topics in Medicinal Chemistry Repetitive Transcranial Magnetic Stimulation for ALS
CNS & Neurological Disorders - Drug Targets The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Acetate Suppresses Lipopolysaccharide-stimulated Nitric Oxide Production in Primary Rat Microglia but not in BV-2 Microglia Cells
Current Molecular Pharmacology 6-hydroxydopamine Lesion of the Mesolimbic Dopamine System Alters Morphine-Induced Conditioned Reinforcement
Current Psychopharmacology Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) An Inflammatory Pathomechanism for Parkinsons Disease?
Current Medicinal Chemistry Phosphatidylserine and Curcumin Act Synergistically to Down-Regulate Release of Interleukin-1β from Lipopolysaccharide-Stimulated Cortical Primary Microglial Cells
CNS & Neurological Disorders - Drug Targets Modulation of γ<sub>2</sub>-MSH Hepatoprotection by Antisense Peptides and Melanocortin Subtype 3 and 4 Receptor Antagonists
Medicinal Chemistry Role of Neurotrophins in Spinal Plasticity and Locomotion
Current Pharmaceutical Design Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?
Current Drug Targets The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Review of Synthesis, Assay, and Prediction of β and γ-secretase Inhibitors
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery